Drug Trial Radar · NCT06001177
A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease
Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Dec 13, 2023
Primary completion
Jan 3, 2025
Study completion Jan 13, 2025
Sponsor
- Lead sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SAIndustry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Aug 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)
Conditions
- Celiac Disease
- Coeliac Disease
Interventions
KAN-101Drug
Dose KAN-101 Intravenous (IV) Infusion
PlaceboDrug
Placebo Intravenous (IV) Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes From Baseline in Villous Height to Crypt Depth (Vh:Cd) as Assessed by Esophagogastroduodenoscopy With Biopsy After 2-week Gluten Challenge (GC)Time frame: Baseline and Day 29
Locations
28 sites in 8 countries. Site status is shown where the registry gives one.
Peak Gastroenterology Associates
Colorado Springs, Colorado
Unlimited Medical Research Group
Hialeah Gardens, Florida
Homestead Associates in Research Inc.
Miami, Florida
Alliance for Multispecialty Research, LLC
Wichita, Kansas
Ochsner Clinic Foundation
New Orleans, Louisiana
Beth Israel Deaconess Medical Center
Boston, Massachusetts
McMaster University
Hamilton, Ontario, Canada
LHSC
London, Ontario, Canada
Centre Intégré de Santé et de Services Sociaux-Chaudière Appalaches - Hôtel-Dieu de Lévis
Lévis, Quebec, Canada
Hopital Du Sacre-Coeur De Montreal
Montreal, Quebec, Canada
Diex Recherche Quebec Inc.
Québec, Quebec, Canada
Tays Research Services
Tampere, Pirkanmaa, Finland
Clinical Research Services Turku
Turku, Southwest Finland, Finland
CRST Helsinki Oy
Helsinki, Uusimaa, Finland
Studiengesellschaft BSF Unternehmergesellschaft
Halle, Saxony-Anhalt, Germany
Connolly Hospital
Dublin, Dublin, Ireland
Our Lady of Lourdes Hospital
Drogheda, Louth, Ireland
Midland Regional Hospital Mullingar
Mullingar, Westmeath, Ireland
Rabin Medical Center
Petah Tikva, Central District, Israel
Sheba Medical Center
Ramat Gan, Central District, Israel
Shaare Zedek Medical Center
Jerusalem, Jerusalem, Israel
Soroka Medical Center
Beersheba, Southern District, Israel
Albert Schweitzer Ziekenhuis, locatie Dordwijk
Dordrecht, South Holland, Netherlands
Gastromed Sp. z o. o.
Torun, Kuyavian-Pomeranian Voivodeship, Poland
Centrum Medyczne Med-Gastr Sp. z o.o.
Lodz, Łódź Voivodeship, Poland
Melita Medical
Wroclaw, Lower Silesian Voivodeship, Poland
WIP Warsaw IBD Point Profesor Kierkuś
Warsaw, Masovian Voivodeship, Poland
MZ Badania Slowik Zymla Spolka Jawna
Knurów, Silesian Voivodeship, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.